Semaglutide (Novo Nordisk)

Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026 Idorsia Ltd (SIX: IDIA) announces an exclusive license and supply agreement with EMS S.A., Brazil’s largest privately-owned pharmaceutical company, to bring QUVIVIQ™ (daridorexant) to patients across Latin America. This partnership marks another milestone in Idorsia’s mission to make QUVIVIQ available worldwide. Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented: “We are very excited to join forces with EMS, a market leader with exceptional commercial reach and expertise. This collaboration is a strategic step forward in our global expansion, ensuring that patients in Latin America will soon have access to our innovative treatment for insomnia – the only medication to have shown improvement on daytime functioning and treat insomnia as a 24-hour disorder. Together, we aim to transform the nights and days for millions of people struggling with this condition.” Under the licensing and supply agreement, EMS will be responsible for the registration and commercialization of QUVIVIQ in Latin America. The filing of a regulatory dossier with ANVISA to obtain marketing authorization in Brazil took place in 2025. Idorsia is entitled to receive: Total milestone compensation of USD 20 million for the execution of the agreement, first filing and launch of QUVIVIQ; Supply price plus double-digit royalties on net sales in Brazil and Mexico; Shared milestone payments due to EMS and royalties by sub-licensees in other Latin America countries. QUVIVIQ – a different kind of insomnia treatment Insomnia affects millions in Latin America, yet current treatments are often associated with next-day drowsiness, risk of dependence, and withdrawal symptoms – leaving a clear unmet need for safer, effective alternatives. QUVIVIQ, discovered by Idorsia, works differently from traditional hypnotics. By selectively blocking orexin receptors, it regulates overactive wake signaling without broadly suppressing brain activity. Its optimized pharmacokinetics promote restorative sleep throughout the entire night, reducing morning sleepiness and improving daytime functioning. Clinical trials published in The Lancet Neurology demonstrated that daridorexant significantly improved sleep onset, sleep maintenance, and self-reported total sleep time at 25mg and 50mg doses compared to placebo. Daridorexant 50 mg also demonstrated a highly significant improvement in daytime functioning compared to placebo. Global availability QUVIVIQ is already marketed in the US, Canada, and multiple European countries, and is available in Japan, Hong Kong, and China through strategic partnerships. In addition, it was recently approved by the Israeli Ministry of Health in Israel, where Idorsia has a license agreement with CTS. The EMS collaboration reinforces Idorsia’s commitment to making QUVIVIQ a global brand. Notes to the editor About insomnia Insomnia is defined as a combination of dissatisfaction with sleep and a significant negative impact on daytime functioning. Dissatisfaction with sleep refers to the difficulty to initiate and/or maintain sleep on at least three nights per week for at least three months, despite adequate opportunity to sleep. Insomnia is a condition of overactive wake signaling and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia. Insomnia as a disorder is quite different from a brief period of poor sleep, and it can take its toll on both physical and mental health. It is a persistent condition with a negative impact on daytime functioning. Idorsia’s research has shown that poor-quality sleep can affect many aspects of daily life, including the ability to concentrate, mood, and energy levels. The goals of managing insomnia are to improve sleep quality and quantity, as well as daytime functioning. Current recommended treatment of insomnia includes sleep hygiene recommendations, cognitive behavioral therapy and pharmacotherapy. About EMS EMS is the largest pharmaceutical company in Brazil, market leader for 20 consecutive years, and part of Grupo NC. With more than 60 years of history and over 10,000 employees, it operates in the segments of medical prescriptions, generics, branded medicines, OTC, and non-retail, manufacturing products for virtually all areas of medicine. The company has production units in Hortolândia (SP), where its advanced R&D Center and modern solid medication packaging plant are located; in Jaguariúna (SP); in Brasília (DF); and in Manaus (AM), operating Novamed, one of the largest solid medication factories in the world. It is also present in Serbia with the pharmaceutical company Galenika and in Italy with the Monteresearch laboratory. Following a solid path of innovation and internationalization of its products and consolidation as a global powerhouse, EMS inaugurated in 2024 Brazil’s first peptide factory, capable of producing GLP-1 analogs such as liraglutide and semaglutide for obesity and type 2 diabetes treatment, serving both domestic and international markets. With operations in 56 countries, EMS conducts one of the largest numbers of clinical studies in Brazil and holds approximately 100 patents granted or under review worldwide. About Idorsia The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact Investor & Media Relations Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 58 844 10 10 investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF

iStock, Anatolii Frolov While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this year. Another player is entering the crowded GLP-1 space. Baseline Therapeutics launched on Tuesday to test the potential of the drug class as a treatment for addiction disorders—a field that industry leaders like Eli Lilly have recently started exploring. Baseline is staying mum about how much money it is starting out with. A spokesperson for the startup told BioSpace in an email that the company is “not able to comment on financing quite yet.” The biotech, based in San Francisco, will use its initial capital to bankroll the late-stage development of its lead asset BT-001, a once-weekly GLP-1 analog being tested for alcohol use disorder (AUD). Baseline has already aligned with the FDA on the drug’s development pathway and is gearing up to launch two randomized, placebo-controlled Phase III studies this year, according to a news release on Tuesday. Baseline is also planning to test BT-001 in other substance use disorders in the future, including those involving opioids. Phase II/III development of the drug for cocaine and methamphetamine use disorders is set to start in the third quarter of this year, according to the biotech’s website . “We are prioritizing execution: an FDA-aligned Phase 3 plan, a weekly dosing pro for adherence, and a multi-indication strategy that can extend beyond [alcohol use disorder],” CEO Nicholas Reville said in a statement. Alongside Reville is Morris Birnbaum, chief scientific officer, who held the same role at Pfizer’s Internal Medicine Research Unit. Using GLP-1s to treat addictive conditions isn’t a new idea . In an August 2023 interview with BioSpace , Michael Glockman, obesity medicine specialist at Revolution Medicine, Health & Fitness, said there is growing evidence to suggest that GLP-1 drugs are “blunting that pleasure response across the board. I think there are so many interplays in the brain that are involved with the dopamine pleasure response, and addiction falls into that.” A Phase II study published in JAMA Psychiatry in February 2025 seems to bear this potential mechanism out . Patients given Novo Nordisk’s semaglutide drank significantly less alcohol and had lower peak breath alcohol levels. Semaglutide treatment also predicted lower heavy drinking over time. The study wasn’t funded by Novo, though its principal author has received consulting fees from the company for other work. Lilly, co-market leader with Novo with its obesity drug Zepbound, has started exploring the use of GLP-1s for AUD and in October last year launched a Phase III trial of brenipatide, a GLP-1/GIP candidate, in patients with the condition. The study is currently recruiting participants and is set to be completed in April 2028.